Novotech Welcomes New Investment From GIC, Temasek, and Existing Investor TPG to Accelerate Global Growth
I'm PortAI, I can summarize articles.
Novotech, a leading biotech clinical research organization, has secured new investments from GIC, Temasek, and existing investor TPG to enhance its global growth. The capital will support organic growth and M&A opportunities, aiming to solidify Novotech's position as a global player in the CRO space. CEO John Moller highlighted the increasing demand for clinical trials in the Asia-Pacific region, with a projected growth rate of 15% annually. The investment will enable Novotech to expand its presence in the US and Europe while maintaining high-quality standards in clinical research.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments